Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Karyopharm Therapeutics Inc. (KPTI)

NEW YORK, NY / ACCESSWIRE / July 24, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Karyopharm Therapeutics Inc. (“Karyopharm” or “the Company”) (NASDAQ: KPTI). Investors who purchased Karyopharm stockare encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/kpti.

The investigation concerns whetherKaryopharmand certain of its officers and/or directors have violated federal securities laws.

On February 22, 2019, in advance of a U.S. Food and Drug Administration (“FDA”) advisory committee meeting to review Karyopharm’s New Drug Application (“NDA”) for selinexor and assess the drug’s risks and benefits, the FDA released a briefing document expressing serious concerns about the safety and efficacy of selinexor (the “FDA Report”). Significantly, the FDA Report revealed that, contrary to Karyopharm’s assurances, the Company’s previously cancelled Phase 2 SOPRA trial had resulted in “worse overall survival” for acute myeloid leukemia (“AML”) patients treated with selinexor, which “highlight[ed] the toxicity of this drug.” The FDA also determined that the toxicity observed with selinexor in AML patients in the SOPRA study was “similar” to that observed in multiple myeloma patients in the Phase 2b STORM study. The FDA unambiguously concluded that “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.”

If you are aware of any facts relating to this investigation, or purchased Karyopharm shares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/kpti. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 553071